Alphabet-backed start-up Isomorphic Labs has added another name to the roster of pharma companies tapping into its AI-based drug discovery engine. Johnson & Johnson's Janssen Biotech unit is the ...
The thick client is making a comeback. Here’s how next-generation local databases like PGlite and RxDB are bringing ...
Isomorphic Lab’s proprietary drug-discovery model is a major advance, but scientists developing open-source tools are left ...
The unified JavaScript runtime standard is an idea whose time has come. Here’s an inside look at the movement for server-side JavaScript interoperability.
SOUTH SAN FRANCISCO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Deep Origin, the computational drug discovery company replacing guesswork with prediction in small molecule drug development, today ...
The unveiling of the Isomorphic Labs Drug Design Engine (IsoDDE) represents a fundamental shift from merely predicting the shape of biological life to actively engineering its functions. While ...
(MENAFN- Swissinfo) Google DeepMind spin-off Isomorphic Labs is building an AI drug design engine that it believes can“solve” all diseases. We spoke to its Chief Technology Officer in Lausanne about ...
Jan 20 (Reuters) - Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday.
Add Yahoo as a preferred source to see more of our stories on Google. Demis Hassabis speaks during the 56th annual World Economic Forum (WEF) meeting in Davos, Switzerland, January 20, 2026.
Jan 20 (Reuters) - Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results